Key takeaways
- China held 19 registration certificates for laparoscopic surgical robots (腔镜手术机器人) as of August 25, 2026, spanning roughly 12 brand systems.
- Domestic brands won about 62% of the laparoscopic robots publicly awarded to public hospitals in the first half of 2026 (17 of 27 disclosed bids).
- United Imaging Surgical's (联影智融) uSurg DoctorX thoracoabdominal endoscopic system cleared the NMPA on July 30, 2026.
- MicroPort's TouMai passed 300 global commercial orders and 200 installations, and posted its first half-year profit.
- New pricing and centralized-procurement rules are starting to shape who can actually buy these machines.
A crowded certificate shelf
For years the dominant question in China's surgical robotics field was simply "when will domestic systems get approved?" As of August 25, 2026, the answer is quantitative: China holds 19 registration certificates for laparoscopic surgical robots (腔镜手术机器人), spanning 15 registration entities and roughly 12 brand systems, according to MedRobot-tracked data cited by VCBeat Health. Eighteen carry the domestic-device designation; one is imported.
The list now reads like a roster: Weigao, MicroPort MedBot (微创机器人), Kangduo, Ronovo, Edge Medical, Shurui, Kangnuosi, Ruilong Nuofu, Agile Medical, Weijing, Tuodao, and United Imaging Surgical (联影智融), among others. What was once a single imported platform's market is now a domestic crowd.
The bid market tilts domestic
Approval is one thing; hospitals actually buying is another. According to MedRobot-tracked public tenders cited by VCBeat Health, 27 laparoscopic surgical robots were publicly awarded to public hospitals in the first half of 2026, and domestic brands won 17 of them — about 62%. A separate industry tally put the domestic share at roughly 63% (17 of 27), consistent with the same underlying data.
The practical meaning: for the first time, Chinese public hospitals are choosing Chinese-made surgical robots at a rate that, combined with price pressure on the imported incumbent, reshapes procurement math. Urology remains the most common entry point, but multi-specialty expansion — gynecology, general surgery, thoracic — is now visible across the newer certificates.
United Imaging enters the main ring
The most recent high-profile clearance came from United Imaging Surgical (武汉联影智融医疗科技有限公司), whose thoracoabdominal endoscopic surgical system, uSurg DoctorX, was approved by the National Medical Products Administration (NMPA, 国家药品监督管理局) on July 30, 2026. The NMPA's own July 2026 approved-devices register lists the product as "胸腹腔内窥镜手术系统" under registration number 国械注准20263011630.
United Imaging is better known globally for medical imaging; the approval signals a deliberate move from diagnosis into interventional and surgical equipment. The company says the system has been validated across hepatobiliary, urology, gastrointestinal, gynecology, and thoracic procedures at leading tertiary hospitals.
TouMai shows the commercial path
While certificates accumulate, MicroPort MedBot's TouMai (图迈) offers the clearest proof that domestic systems can sell. The company disclosed that, as of mid-2026, TouMai had passed 300 global commercial orders and 200 installations, with overseas deployments across more than 60 countries and regions. MicroPort MedBot's interim results guidance pointed to a first-half net profit of 28–40 million yuan (≈ US$3.9M–5.6M / HK$31M–44M) — its first profitable half-year — on revenue up roughly 200–230% year on year.
That combination — scale of orders, installed base, and profitability — is the milestone the rest of the field is chasing, because surgical robots priced in the millions of RMB only make economic sense when utilization is high.
There is a caveat the order numbers hide: a robot sitting idle in an operating room is a sunk cost, not a revenue engine. Hospitals need trained surgical teams, and procedures must be scheduled densely to justify the price. That is why several newer certificates are deliberately widening their approved specialties — a device that only serves urology fills its calendar far less often than one cleared for urology, gynecology, general, and thoracic work. Utilization, not clearance, is becoming the real competitive battleground.
Why this matters outside China
Two forces are converging. On the demand side, China's hospital count is large and its surgical robot penetration is still low — industry figures cited by medtech outlets put the installed base at only about 600 units against thousands of tertiary hospitals. On the policy side, a draft pricing guideline (征求意见稿) from the National Healthcare Security Administration began sketching how surgical-robot assistance gets reimbursed, and a July 2026 notice brought laparoscopic surgical systems into provincial centralized procurement. Both lower the cost barrier for smaller hospitals — and both are still in flux.
For global readers, the takeaway is that a once-closed, import-dominated market is becoming a domestic competitive one, with implications for pricing and adoption worldwide.
Honest limitations
Key figures come from MedRobot-tracked tender data reported by VCBeat Health, company disclosures, and the NMPA public register; we did not independently verify each hospital tender. The "62%" and "63%" readings derive from the same 27-bid sample and should be read as indicative, not a census of all purchases. Profit and order figures are company guidance/disclosures, not audited results. The pricing guideline is a draft for comment (征求意见稿), not yet finalized policy, and the centralized-procurement notice's long-term effect is not yet measurable.
What readers can do now
- If you work in medtech, watch China's NMPA clearance list — it is now the fastest-moving surgical-robot approval track outside the US.
- If you are a clinician or administrator, compare not just sticker price but utilization rate and service network before adopting.
- If you invest or procure, treat "certificates held" and "units actually installed and used" as two different, separately tracked metrics.